Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) EBIT (2020 - 2025)

Ovid Therapeutics (OVID) has disclosed EBIT for 6 consecutive years, with -$12.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBIT rose 5.32% year-over-year to -$12.5 million, compared with a TTM value of -$40.9 million through Sep 2025, up 41.07%, and an annual FY2024 reading of -$61.9 million, down 4.39% over the prior year.
  • EBIT was -$12.5 million for Q3 2025 at Ovid Therapeutics, down from -$5.1 million in the prior quarter.
  • Across five years, EBIT topped out at $176.6 million in Q1 2021 and bottomed at -$26.4 million in Q4 2021.
  • Average EBIT over 5 years is -$4.3 million, with a median of -$13.2 million recorded in 2024.
  • The sharpest move saw EBIT skyrocketed 969.98% in 2021, then tumbled 109.21% in 2022.
  • Year by year, EBIT stood at -$26.4 million in 2021, then skyrocketed by 53.81% to -$12.2 million in 2022, then crashed by 49.41% to -$18.2 million in 2023, then surged by 41.05% to -$10.7 million in 2024, then decreased by 16.8% to -$12.5 million in 2025.
  • Business Quant data shows EBIT for OVID at -$12.5 million in Q3 2025, -$5.1 million in Q2 2025, and -$12.5 million in Q1 2025.